Rate My Professor Bu Yeap

Professor Bu Yeap is a Professor and Head of Division, Internal Medicine, in the UWA Medical School at the University of Western Australia. Concurrently, he is a consultant endocrinologist in the Department of Endocrinology and Diabetes at Fiona Stanley Hospital, Perth, where he manages inpatient and outpatient care for individuals with endocrine disorders and diabetes. He also mentors physician trainees and instructs medical students. Bu Yeap earned his MBBS, PhD with Distinction in 2001, and Fellowship of the Royal Australasian College of Physicians (FRACP) in 1996. He joined UWA as a Senior Lecturer in 2000, advanced to Associate Professor in 2007, and was promoted to Professor (Level E) in 2016.

Bu Yeap's research centers on epidemiological and clinical investigations into hormones and their associations with health outcomes in men, as well as the interplay between hormones, diabetes, and cardiovascular risk factors. Key areas of interest encompass testosterone levels in male ageing, the link between testosterone and cardiovascular risk in middle-aged and older men, and the relationships among obesity, diabetes, and cardiovascular disease. As an investigator in the Australia-wide Testosterone for the Prevention of Type 2 Diabetes Mellitus (T4DM) randomized controlled trial, his work has advanced understanding of testosterone therapy in preventing type 2 diabetes. Boasting over 300 publications, including more than 250 original research articles, and exceeding 10,000 citations on Scopus, notable contributions include "Endogenous Testosterone, Testosterone Treatment, and Cardiovascular Health Outcomes in Men" (Journal of Clinical Endocrinology & Metabolism, 2026), "Testosterone, Diabetes Risk, and Diabetes Prevention in Men" (Endocrinology and Metabolism Clinics of North America, 2022), and serving as first author on the Endocrine Society of Australia’s Position Statement on Male Hypogonadism (Medical Journal of Australia, 2016). His accolades include the South Metro Health Service Researcher of the Year in 2021 and presidency of the Endocrine Society of Australia from 2020 to 2022. Currently, he leads projects on incretin agonists for diabetes prevention in Aboriginal populations and novel treatments for obesity, diabetes, and frailty.